This study demonstrated that blunting dystrophic heart inflammation through PKCθ inhibition can ameliorate heart phenotype and improve heart function in a novel model of DMD-related cardiac pathology. The gene discussed is PRRT2; the disease is Duchenne muscular dystrophy.